AI Terminal
Haleon PLC
Report Publication Announcement • Feb 29, 2024
5111_10-k_2024-02-29_a8282362-d7e7-436a-acd7-4cddedcd1dc5.html
Report Publication Announcement
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 8643E
Haleon PLC
29 February 2024
Haleon plc: Preliminary 2023 Full Year Results
29 February 2024: Haleon plc's preliminary full year results for the year ended 31 December 2023 are available at: http://www.rns-pdf.londonstockexchange.com/rns/8643E_1-2024-2-28.pdf.
The full year results statement will also be available on the Haleon website www.haleon.com/investors, and the results have been submitted in full unedited text to the Financial Conduct Authority's National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Investor Presentation
A recorded results presentation by Brian McNamara, Chief Executive Officer, and Tobias Hestler, Chief Financial Officer, will be available shortly after 7am GMT (8am CET) on 29 February 2024 and can be accessed at www.haleon.com/investors. This will be followed by a Q&A session at 9am GMT (10am CET).
For analysts and shareholders wishing to ask questions, please use the dial-in details below which will have a Q&A facility:
| UK: | +44 800 279 3956 |
| US: | +1 866 291 4166 |
| All other: | +44 (0) 20 7107 0613 |
| Passcode: | 43700369 |
An archived webcast of the presentation will be available later on the day of the results and can be accessed at www.haleon.com/investors.
This information contains regulated information as per 6.3.7R of the Disclosure and Transparency Rules of the Financial Conduct Authority.
| Enquiries | |||
| Investors | Media | ||
| Sonya Ghobrial | +44 7392 784784 | Zoë Bird | +44 7736 746167 |
| Rakesh Patel | +44 7552 484646 | Nidaa Lone | +44 7841 400607 |
| Emma White | +44 7823 523562 | ||
| Email: [email protected] | Email: [email protected] |
About Haleon
Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
FR UWSWRSOUUUAR